ENXTPA:ALCJ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Crossject Société Anonyme

Executive Summary

Crossject Société Anonyme develops needle-free injection systems. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Crossject Société Anonyme's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALCJ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.3%

ALCJ

1.4%

FR Medical Equipment

-0.1%

FR Market


1 Year Return

116.6%

ALCJ

56.1%

FR Medical Equipment

-7.2%

FR Market

Return vs Industry: ALCJ exceeded the French Medical Equipment industry which returned 56.1% over the past year.

Return vs Market: ALCJ exceeded the French Market which returned -7.2% over the past year.


Shareholder returns

ALCJIndustryMarket
7 Day3.3%1.4%-0.1%
30 Day-22.1%-11.3%1.9%
90 Day38.2%1.2%2.0%
1 Year116.6%116.6%56.5%56.1%-5.1%-7.2%
3 Year-38.2%-40.1%51.3%48.8%9.1%-0.4%
5 Year-36.5%-39.4%149.2%141.5%41.4%22.3%

Price Volatility Vs. Market

How volatile is Crossject Société Anonyme's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Crossject Société Anonyme undervalued compared to its fair value and its price relative to the market?

19.92x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALCJ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALCJ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALCJ is unprofitable, so we can't compare its PE Ratio to the FR Medical Equipment industry average.

PE vs Market: ALCJ is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALCJ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALCJ is overvalued based on its PB Ratio (19.9x) compared to the FR Medical Equipment industry average (3.2x).


Next Steps

Future Growth

How is Crossject Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

9.9%

Forecasted Healthcare industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALCJ's forecast earnings growth is above the savings rate (0.6%).

Earnings vs Market: Insufficient data to determine if ALCJ's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALCJ's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if ALCJ's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALCJ's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Crossject Société Anonyme performed over the past 5 years?

-16.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALCJ is currently unprofitable.

Growing Profit Margin: ALCJ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALCJ is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare ALCJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALCJ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-5.3%).


Return on Equity

High ROE: ALCJ has a negative Return on Equity (-238.02%), as it is currently unprofitable.


Next Steps

Financial Health

How is Crossject Société Anonyme's financial position?


Financial Position Analysis

Short Term Liabilities: ALCJ's short term assets (€11.8M) exceed its short term liabilities (€5.2M).

Long Term Liabilities: ALCJ's short term assets (€11.8M) do not cover its long term liabilities (€16.2M).


Debt to Equity History and Analysis

Debt Level: ALCJ's debt to equity ratio (348.3%) is considered high.

Reducing Debt: Insufficient data to determine if ALCJ's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALCJ has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALCJ has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.9% each year


Next Steps

Dividend

What is Crossject Société Anonyme current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALCJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALCJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALCJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALCJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALCJ's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average board tenure


CEO

Patrick Alexandre

no data

Tenure

€161,840

Compensation

Mr. Patrick Alexandre co-founded Crossject Société Anonyme (f/k/a, Crossject Medical Technology) in 2001 and has been its Chairman of the Executive Board since 2012 and serves as its Chief Executive Office ...


Board Members

NamePositionTenureCompensationOwnership
Philippe Monnot
Chairman of Supervisory Boardno datano datano data
Patrice Coissac
Member of Supervisory Boardno datano datano data
Eric Nemeth
Independent Vice Chairman of the Supervisory Board8.67yrsno datano data
Yannick Plétan
Member of Supervisory Board1yrno datano data
Jean-Francois Loumeau
Member of Supervisory Board2yrsno datano data

2.0yrs

Average Tenure

Experienced Board: ALCJ's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.4%.


Top Shareholders

Company Information

Crossject Société Anonyme's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Crossject Société Anonyme
  • Ticker: ALCJ
  • Exchange: ENXTPA
  • Founded: 1997
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €76.082m
  • Shares outstanding: 25.36m
  • Website: https://www.crossject.com

Number of Employees


Location

  • Crossject Société Anonyme
  • 6 Rue Pauline Kergomard
  • Dijon
  • Burgundy
  • 21000
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALCJENXTPA (Euronext Paris)YesCommon StockFREURFeb 2014
74CDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014
CRJT.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDFeb 2014

Biography

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 04:44
End of Day Share Price2020/09/18 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.